GW Pharmaceuticals, the developer of cannabis-based medicinal products, has released a puff piece about a favourable review of its Sativex product in a US medical journal.
The "Journal of Pain", the official journal of the American Pain Society, has published the full results from a Phase IIb dose-ranging trial evaluating the efficacy and safety of Sativex in the treatment of pain in patients with advanced cancer, who experience inadequate pain relief (analgesia) during optimised chronic pain suppression therapy.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
-
Bargain bling: invest in luxury stocks while they are out of style?Although sellers of luxury goods are more insulated than many industries, economic headwinds have been holding them back too. Is now a good time to pick up a bargain?
-
Inheritance tax pension rule could make six times more over 55s liable – how investing in onshore bonds can helpFinancial advisers have switched to recommending onshore bonds to help clients avoid inheritance tax and pass on wealth
